PloS oneSep 9, 2026

Effects of GLP-1 receptor drugs on patients with precancerous pancreatic cysts: Study plan for a multi-center patient group

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 10, 2026

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) are common cystic pancreatic neoplasms with a potential to progress to malignancy.

The prevalence of IPMNs is increasing, which raises concerns regarding treatment options.
GLP-1 receptor agonists are widely used for managing diabetes and obesity.
There are questions about how GLP-1 receptor agonists may affect pancreatic health.
This study investigates the potential link between GLP-1 RA use and the progression of IPMNs.

Simplified

Intraductal papillary mucinous neoplasms (IPMNs) are among the most common cystic pancreatic neoplasms, with a potential to progress to malignancy. The increasing prevalence of IPMNs, coupled with the widespread use of GLP-1 receptor agonists (GLP-1 RAs) for diabetes and obesity management, raises concerns about the safety of these medications in patients with preexisting pancreatic conditions. Despite their proven metabolic benefits, questions remain about their impact on pancreatic pathology. This study investigates the association between GLP-1 RA use and IPMN progression to address this critical gap in the current literature.

Full Text

Full text is available at the source.

View Full Text ↗

Effects of GLP-1 receptor drugs on patients with precancerous pancreatic cysts: Study plan for a multi-center patient group

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief